PCSK9 pipeline shows signs of saturation
Astrazeneca and Ionis’s discontinuation could herald a nervous time for others in this space.
No let-up in Covid-19 vaccine trials
A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.
AC Immune backs alpha-synuclein despite recent setbacks
The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.
